|
1
|
Defining Cancer, . National Cancer
Institute. https://www.cancer.gov/about-cancer/understanding/what-is-cancerAccessed
June 10, 2014.
|
|
2
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wu J, Qiu T, Pan P, Yu D, Ju Z, Qu X, Gao
X, Mao C and Wang L: Detection of serum anti-p53 antibodies from
patients with colorectal cancer in china using a combination of
p53- and phage-ELISA. Asian Pac J Cancer Prev. 12:2921–2924.
2011.PubMed/NCBI
|
|
4
|
Peetla C, Bhave R, Vijayaraghavalu S,
Stine A, Kooijman E and Labhasetwar V: Drug resistance in breast
cancer cells: Biophysical characterization of and doxorubicin
interactions with membrane lipids. Mol Pharm. 7:2334–2348. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Seddon AM, Casey D, Law RV, Gee A, Templer
RH and Ces O: Drug interactions with lipid membranes. Chem Soc ReV.
38:2509–2519. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Righetti SC, Perego P, Carenini N, Corna
E, Dal Bo L, Cedrola S, La Porta CA and Zunino F: Molecular
alterations of cells resistant to platinum drugs: Role of PKCalpha.
Biochim Biophys Acta. 1763:93–100. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dai Z, Huang Y and Sadée W: Growth factor
signaling and resistance to cancer chemotherapy. Curr Top Med Chem.
4:1347–1356. 2004.PubMed/NCBI
|
|
8
|
Rossi S: Australian Medicines Handbook
(2013 edition). The Australian Medicines Handbook Unit Trust;
Adelaide: 2013
|
|
9
|
Tolba MF and Abdel-Rahman SZ:
Pterostilbine, an active component of blueberries, sensitizes colon
cancer cells to 5-fluorouracil cytotoxicity. Sci Rep. 5:152392015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ohtsu A: Chemotherapy for metastatic
gastric cancer: Past, present, and future. J Gastroenterol.
43:256–264. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Williams TM and Lisanti MP: The caveolin
proteins. Genome Biol. 5:2142004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tang Z, Scherer PE, Okamoto T, Song K, Chu
C, Kohtz DS, Nishimoto I, Lodish HF and Lisanti MP: Molecular
cloning of caveolin-3, a novel member of the caveolin gene family
expressed predominantly in muscle. J Biol Chem. 271:2255–2261.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Scherer PE, Okamoto T, Chun M, Nishimoto
I, Lodish HF and Lisanti MP: Identification, sequence, and
expression of caveolin-2 defines a caveolin gene family. Proc Natl
Acad Sci USA. 93:131–135. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hill MM, Bastiani M, Luetterforst R,
Kirkham M, KirKham A, Nixon SJ, Walser P, Abankwa D, Oorschot VM,
Martin S, et al: PTRF-Cavin, a conserved cytoplasmic protein
required for caveola formation and function. Cell. 132:113–124.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hansen CG and Nichols BJ: Exploring the
caves: Cavins, caveolins and caveolae. Trends Cell Biol.
20:177–186. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Briand N, Dugail I and Le Lay S: Cavin
proteins: New players in the caveolae field. Biochimie. 93:71–77.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gillet JP and Gottesman MM: Mechanisms of
multidrug resistance in cancer. Methods Mol Biol. 596:47–76. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li S, Couet J and Lisanti MP: Src tyrosine
kinases, Galpha subunits, and H-Ras share a common
membrane-anchored scaffolding protein, caveolin. Caveolin binding
negatively regulates the auto-activation of Src tyrosine kinases. J
BiolChem. 271:29182–29013. 1996.
|
|
19
|
Selleri S, Arnaboldi F, Palazzo M, Hussein
U, Balsari A and Rumio C: Caveolin-1 is expressed on multipotent
cells of hair follicles and might be involved in their resistance
to chemotherapy. Br J Dermatol. 153:506–513. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shajahan AN, Wang A, Decker M, Minshall
RD, Liu MC and Clarke R: Caveolin-1 tyrosine phosphorylation
enhances paclitaxel-mediated cytotoxicity. J BiolChem.
282:5934–5943. 2007.
|
|
21
|
Tse EY, Ko FC, Tung EK, Chan LK, Lee TK,
Ngan ES, Man K, Wong AS, Ng IO and Yam JW: Caveolin-1
overexpression is associated with hepatocellular carcinoma
tumourigenesis and metastasis. J Pathol. 226:645–653. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tang Y, Zeng X, He F, Liao Y, Qian N and
Toi M: Caveolin-1 is related to invasion, survival, and poor
prognosis in hepatocellular cancer. Med Oncol. 29:977–984. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Selleri S, Arnaboldi F, Palazzo M, Hussein
U, Balsari A and Rumio C: Caveolin-1 is expressed on multipotent
cells of hair follicles and might be involved in their resistance
to chemotherapy. Br J Dermatol. 153:506–513. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shajahan AN, Wang A, Decker M, Minshall
RD, Liu MC and Clarke R: Caveolin-1 tyrosine phosphorylation
enhances paclitaxel-mediated cytotoxicity. J BiolChem.
282:5934–5943. 2007.
|
|
25
|
Thomas S, Overdevest JB, Nitz MD, Williams
PD, Owens CR, Sanchez-Carbayo M, Frierson HF, Schwartz MA and
Theodorescu D: Src and Caveolin-1 reciprocally regulate metastasis
via a common downstream signaling pathways in bladder cancer.
Cancer Res. 71:832–841. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Meena AS, Sharma A, Kumari R, Mohammad N,
Singh SV and Bhat MK: Inherent and acquired resistance to
paclitaxel in hepatocellular carcinoma: Molecular events involved.
PLoS One. 8:e615242013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
American Cancer Society, . Cancer Facts
& Figures 2014. American Cancer Society; Atlanta, GA: 2014
|
|
29
|
Colon Cancer Treatment
(PDQ®)–Patient Version. National Cancer Institute;
https://www.cancer.gov/types/colorectal/patient/colon-treatment-pdq#section/allAccessed
June 29, 2014.
|
|
30
|
Cunningham D, Atkin W, Lenz HJ, Lynch HT,
Minsky B, Nordlinger B and Starling N: Colorectal cancer. Lancet.
375:1030–47. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Szakács G, Paterson JK, Ludwig JA,
Booth-Genthe C and Gottesman MM: Targeting multidrug resistance in
cancer. Nat Rev Drug Discov. 5:219–234. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Germann UA and Chambers TC: Molecular
analysis of the multidrug transporter, P-glycoprotein.
Cytotechnology. 27:31–60. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xu Y, Zhi F, Xu G, Tang X, Lu S, Wu J and
Hu Y: Overcoming multidrug-resistance in vitro and in vivo using
the novel P-glycoprotein inhibitor 1416. Biosci Rep. 32:559–566.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Nimri L, Barak H, Graeve L and Schwartz B:
Restoration of caveolin-1 expression suppresses growth,
membrane-type-4 metalloproteinase expression and
metastasis-associated activities in colon cancer cells. Mol
Carcinog. 52:859–870. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bender FC, Reymond MA, Bron C and Quest
AF: Caveolin-1 levels are down-regulated in human colon tumors, and
ectopic expression of caveolin-1 in colon carcinoma cell lines
reduces cell tumorigenicity. Cancer Res. 60:5870–5888.
2000.PubMed/NCBI
|
